About Codexis (NASDAQ:CDXS)
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorIndustrial Products
SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100
Debt
Debt-to-Equity Ratio0.02%
Current Ratio1.80%
Quick Ratio1.76%
Price-To-Earnings
Trailing P/E Ratio-23.40
Forward P/E Ratio-47.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$50.02 million
Price / Sales11.90
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book22.16
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-22,990,000.00
Net Margins-45.97%
Return on Equity-103.42%
Return on Assets-51.64%
Miscellaneous
Employees116
Outstanding Shares52,680,000
Codexis (NASDAQ:CDXS) Frequently Asked Questions
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis (NASDAQ:CDXS) posted its earnings results on Thursday, March, 8th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.05 by $0.03. The biotechnology company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $22.97 million. Codexis had a negative return on equity of 103.42% and a negative net margin of 45.97%. The company's revenue was up 117.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.07) earnings per share. View Codexis' Earnings History.
What price target have analysts set for CDXS?
2 equities research analysts have issued 1-year price targets for Codexis' stock. Their forecasts range from $11.00 to $12.00. On average, they expect Codexis' share price to reach $11.50 in the next year. View Analyst Ratings for Codexis.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include Westlake Chemical (WLKP), Green Plains (GPRE), Green Plains Partners (GPP), FutureFuel (FF), Renewable Energy Group (REGI), REX American Resources (REX), Amyris Biotechnologies (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), China Insonline (WAYS), Aemetis (AMTX), CTD (CTDH), Gevo (GEVO) and OriginClear (OCLN).
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Mr. John J. Nicols, Pres, CEO & Director (Age 54)
- Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 65)
- Mr. Michael D. A. Aldridge B.Sc (Hons)., MApFin, Sr. VP of Corp. & Strategic Devel. (Age 51)
- Dr. James J. Lalonde Ph.D., Sr. VP of R&D (Age 57)
- Mr. Keith McKay, Director of Bus. Devel.
Has Codexis been receiving favorable news coverage?
Media stories about CDXS stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.01 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.02 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Codexis?
Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Codexis' stock price today?
One share of CDXS stock can currently be purchased for approximately $11.45.
How big of a company is Codexis?
Codexis has a market capitalization of $592.62 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.
How can I contact Codexis?
Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]
MarketBeat Community Rating for Codexis (CDXS)
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Codexis (NASDAQ:CDXS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Codexis in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 1.77%. The high price target for CDXS is $12.00 and the low price target for CDXS is $11.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.67 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.50 | $11.50 | $8.3333 | $7.8125 |
| Price Target Upside: | 1.77% upside | 3.60% upside | 42.45% upside | 0.48% downside |
Codexis (NASDAQ:CDXS) Consensus Price Target History
Codexis (NASDAQ:CDXS) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Codexis (NASDAQ:CDXS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Codexis (NASDAQ CDXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.80%
Institutional Ownership Percentage: 65.13%
Codexis (NASDAQ CDXS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/3/2018 | David V Smith | Director | Sell | 6,000 | $10.37 | $62,220.00 | |  |
| 3/29/2018 | Thomas R Baruch | Director | Sell | 25,000 | $11.05 | $276,250.00 | 184,670 | |
| 3/27/2018 | Dennis P Wolf | Director | Sell | 41,666 | $11.15 | $464,575.90 | 157,920 | |
| 3/23/2018 | John J Nicols | Insider | Sell | 22,465 | $11.57 | $259,920.05 | 1,078,990 | |
| 3/21/2018 | Bernard J Kelley | Director | Sell | 10,206 | $12.22 | $124,717.32 | | |
| 9/14/2017 | Ventures Vii Affiliates F Vivo | Major Shareholder | Sell | 1,060,000 | $5.78 | $6,126,800.00 | | |
| 8/21/2017 | Patrick Y Yang | Director | Buy | 10,000 | $3.98 | $39,800.00 | 348,234 | |
| 11/15/2016 | Patrick Y Yang | Director | Buy | 10,000 | $4.83 | $48,300.00 | 320,340 | |
| 9/8/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 111,600 | $4.25 | $474,300.00 | | |
| 8/29/2016 | Dennis P Wolf | Director | Sell | 18,000 | $4.22 | $75,960.00 | 132,360 | |
| 8/24/2016 | Bernard J Kelley | Director | Sell | 12,643 | $4.26 | $53,859.18 | 234,906 | |
| 8/16/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 86,894 | $4.25 | $369,299.50 | | |
| 8/15/2016 | Vivo Ventures Vii, Llc | Major Shareholder | Sell | 50,000 | $4.27 | $213,500.00 | | |
| 8/4/2016 | Ventures Fund Vii L.P. Vivo | Major Shareholder | Sell | 80,000 | $4.22 | $337,600.00 | | |
| 11/11/2015 | James Lalonde | SVP | Sell | 9,441 | $3.52 | $33,232.32 | 168,011 | |
| 9/11/2015 | Patrick Y Yang | Director | Buy | 10,000 | $3.47 | $34,700.00 | 290,246 | |
| 9/10/2015 | Bernard J. Kelley | Director | Sell | 5,200 | $3.45 | $17,940.00 | 193,146 | |
| 8/24/2015 | Patrick Y Yang | Director | Buy | 10,000 | $3.84 | $38,400.00 | 280,246 | |
| 8/14/2015 | Patrick Y Yang | Director | Buy | 20,000 | $3.97 | $79,400.00 | | |
| 6/15/2015 | Dennis P Wolf | Director | Sell | 35,416 | $4.10 | $145,205.60 | | |
| 11/18/2014 | Patrick Y Yang | Director | Buy | 20,000 | $2.35 | $47,000.00 | | |
| 11/17/2014 | Patrick Y Yang | Director | Buy | 20,000 | $2.34 | $46,800.00 | | |
| 8/12/2014 | Patrick Y Yang | Director | Buy | 60,000 | $2.22 | $133,200.00 | | |
| 3/8/2013 | John J Nicols | CEO | Buy | 27,000 | $2.42 | $65,340.00 | | |
| 3/7/2013 | John J Nicols | CEO | Buy | 54,000 | $2.22 | $119,880.00 | | |
| 3/4/2013 | David D O'toole | CFO | Buy | 10,000 | $2.02 | $20,200.00 | | |
| 11/12/2012 | David D O'toole | CFO | Buy | 5,000 | $2.20 | $11,000.00 | | |
| 9/14/2012 | David D O'toole | CFO | Buy | 5,000 | $2.78 | $13,900.00 | | |
| 9/14/2012 | Douglas T Sheehy | SVP | Sell | 3,800 | $2.76 | $10,488.00 | | |
(Data available from 1/1/2013 forward)
Codexis (NASDAQ CDXS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Review: FutureFuel (FF) & Codexis (CDXS)
www.americanbankingnews.com - April 24 at 11:04 PM |
 | Porton Pharma Solutions and Codexis Launch Global Partnership
finance.yahoo.com - April 23 at 9:11 AM |
| Codexis (CDXS) Upgraded at BidaskClub
www.americanbankingnews.com - April 18 at 12:16 PM |
| Codexis (CDXS) to Post Q2 2018 Earnings of ($0.09) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - April 18 at 8:05 AM |
| Brokers Offer Predictions for Codexis' Q1 2019 Earnings (CDXS)
www.americanbankingnews.com - April 17 at 6:51 AM |
 | Codexis (CDXS) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:28 PM |
| $13.50 Million in Sales Expected for Codexis (CDXS) This Quarter
www.americanbankingnews.com - April 11 at 4:13 AM |
| Brokerages Expect Codexis (CDXS) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - April 9 at 9:14 AM |
| Contrasting Codexis (CDXS) & Sensient Technologies (SXT)
www.americanbankingnews.com - April 8 at 1:30 AM |
| Why Codexis, Inc. Stock Is Tumbling Today
finance.yahoo.com - April 6 at 4:39 PM |
 | After-Hours Stock Movers 04/05: (GCAP) (OGEN) (PSMT) Higher; (CDXS) (ETH) (ORBC) Lower (more...)
www.streetinsider.com - April 6 at 9:56 AM |
| Codexis prices stock offering at $9.25; shares down 10% premarket
seekingalpha.com - April 6 at 6:42 AM |
| Equities Analysts Offer Predictions for Codexis' Q1 2018 Earnings (CDXS)
www.americanbankingnews.com - April 6 at 6:39 AM |
 | Codexis Announces Pricing of Public Offering of Common Stock
feeds.benzinga.com - April 5 at 10:06 PM |
| Codexis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 5 at 4:26 PM |
| Codexis (CDXS) Director Sells $62,220.00 in Stock
www.americanbankingnews.com - April 5 at 1:23 PM |
| Codexis to Present at H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco
finance.yahoo.com - April 5 at 9:00 AM |
| Codexis Forecasted to Earn Q3 2018 Earnings of ($0.02) Per Share (CDXS)
www.americanbankingnews.com - April 5 at 8:41 AM |
| Codexis (CDXS) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - April 3 at 5:52 PM |
| Codexis (CDXS) Cut to Hold at BidaskClub
www.americanbankingnews.com - March 30 at 6:14 PM |
| Edited Transcript of CDXS earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 30 at 4:29 PM |
| Codexis, Inc. (CDXS) Director Thomas R. Baruch Sells 25,000 Shares
www.americanbankingnews.com - March 30 at 1:14 PM |
| Codexis (CDXS) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - March 28 at 6:32 PM |
| Insider Selling: Codexis, Inc. (CDXS) Director Sells 41,666 Shares of Stock
www.americanbankingnews.com - March 28 at 1:16 PM |
| $13.50 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - March 25 at 7:15 AM |
| Insider Selling: Codexis, Inc. (CDXS) Insider Sells 22,465 Shares of Stock
www.americanbankingnews.com - March 23 at 10:14 PM |
| Zacks: Brokerages Anticipate Codexis, Inc. (CDXS) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - March 23 at 9:30 AM |
| Bernard J. Kelley Sells 10,206 Shares of Codexis, Inc. (CDXS) Stock
www.americanbankingnews.com - March 22 at 7:32 PM |
| Codexis (CDXS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 14 at 7:17 PM |
| Codexis (CDXS) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 12 at 5:30 PM |
| Codexis (CDXS) PT Set at $12.00 by HC Wainwright
www.americanbankingnews.com - March 12 at 2:24 PM |
| Here's Why Codexis Dropped as Much as 14.6% Today
finance.yahoo.com - March 9 at 5:27 PM |
| Codexis misses Street 4Q forecasts
finance.yahoo.com - March 9 at 10:02 AM |
| Codexis (CDXS) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 8 at 9:12 PM |
| Codexis Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 8 at 5:19 PM |
| Codexis Q4 Earnings Preview
feeds.benzinga.com - March 8 at 10:16 AM |
| Codexis Inc (NASDAQ:CDXS): Is Breakeven Near?
finance.yahoo.com - March 8 at 9:51 AM |
| $22.96 Million in Sales Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - March 8 at 9:50 AM |
| Telemark Asset Management LLC Increases Stake in Codexis, Inc. (CDXS)
www.americanbankingnews.com - March 6 at 11:12 AM |
| Codexis, Inc. (CDXS) Expected to Post Earnings of $0.05 Per Share
www.americanbankingnews.com - March 6 at 3:08 AM |
| Codexis, Inc. (CDXS) Shares Sold by Cortina Asset Management LLC
www.americanbankingnews.com - February 28 at 1:27 PM |
| Codexis (CDXS) to Release Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM |
| Head to Head Survey: Codexis (CDXS) vs. Biohaven Pharmaceutical (BHVN)
www.americanbankingnews.com - February 25 at 1:18 PM |
| Codexis, Inc. (CDXS) Expected to Post Quarterly Sales of $22.96 Million
www.americanbankingnews.com - February 19 at 4:30 AM |
| Codexis (CDXS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 15 at 7:24 PM |
| Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
finance.yahoo.com - February 15 at 8:46 AM |
| Codexis to Present at the 25th International Molecular Medicine Tri-Conference
feeds.benzinga.com - February 12 at 7:43 AM |
| Zacks Investment Research Lowers Codexis (CDXS) to Sell
www.americanbankingnews.com - February 9 at 7:16 PM |
| $0.05 EPS Expected for Codexis, Inc. (CDXS) This Quarter
www.americanbankingnews.com - January 31 at 1:20 PM |
 | Commit To Purchase Codexis At $7.50, Earn 19.2% Annualized Using Options
www.nasdaq.com - January 24 at 4:45 PM |
Codexis (NASDAQ:CDXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Codexis (NASDAQ:CDXS) Income Statement, Balance Sheet and Cash Flow Statement
Codexis (NASDAQ CDXS) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
